You are here

Article Text

Article menu
Download PDFPDF
Miscellaneous
Journal club
Azithromycin 250 mg daily reduces exacerbation frequency and improves quality of life in selected COPD patients
  1. K D S Pannu
  1. Correspondence toDr K D S Pannu, ST5, Respiratory Medicine, Basildon University Hospital, Nethermayne, Basildon SS16 5NL, UK; kds_pannu{at}yahoo.com

https://doi.org/10.1136/thoraxjnl-2011-201189

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    This multicentre study randomised 1142 subjects at risk of acute exacerbations of chronic obstructive pulmonary disease (COPD) to receive azithromycin 250 mg daily (n=570) or placebo (n=572) for 1 year, in addition to usual care. The enrolled subjects were allowed to continue on inhaled treatments and/or oxygen. None of the subjects were on oral theophylline. The primary outcome, time …

    View Full Text